CHICAGO, Dec. 7, 2012 /PRNewswire/ -- Positron
Corporation (OTCBB: POSC) posts their first commercial sale and
shipment of Active Pharmaceutical Ingredient (API) grade
Strontium-82 to a North American pharmaceutical company. Manhattan
Isotope Technology (MIT), LLC, a wholly owned subsidiary of
Position Corporation, completed the processing, production and
shipment of their API grade strontium-82, which was delivered this
week. The API was produced from target material received from one
of its foreign collaborators for target irradiation.
Strontium-82, API, is used exclusively to manufacture
rubidium-82 generators and is the most widely accepted Positron
Emission Tomography (PET) agent utilized in myocardial perfusion
imaging.
"I and my team at MIT, have been
developing our isotope production business for many years. This API
shipment is a culmination of our company's expertise, research
& development efforts, dedication to our isotope program and
the efficiencies of MIT's Sr-82
production facility," said Jason
Kitten, President of MIT and
Positron's Director of Radiopharmaceutical & Radioisotope
Production. "Positron's commitment to Rb-82 based cardiac PET
continues by addressing the single largest factor limiting its
growth, Strontium-82 production. By building upon the current
production base and increasing capacity, Positron will bring
diversity and confidence to Sr-82 supply, thus providing further
assurance that this technology will be a dependable, reliable
modality for the nuclear cardiology community. The building
blocks of Positron's vertical integration model for cardiac PET now
includes Sr-82 API production and with this asset secured we've
achieved a key milestone in our end-to-end solution's
strategy."
About Positron: Positron Corporation is a nuclear
medicine healthcare company vertically integrating all the segments
of nuclear cardiology—providing an end-to-end solution for cardiac
PET. Through proprietary PET imaging systems,
radiopharmaceuticals and radioisotopes solutions, Positron enables
healthcare providers to more accurately diagnose disease and
improve patient outcomes, while practicing cost effective medicine.
Positron's unique products, market position and approach in
securing the supply chain are substantial advantages, further
accelerating the adoption of cardiac PET and growth of nuclear
cardiology. Positron is redefining the industry. More
information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this
document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance. These statements may involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Positron
Corporation to be materially different from future results,
performance or achievements expressed or implied by such
forward-looking statements. Positron assumes no obligation to
publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the
future. Our actual results may differ materially from the
results anticipated in these forward-looking statements due to a
variety of factors, including, without limitation those set forth
as "Risk Factors" in our filings with the Securities and Exchange
Commission.
SOURCE Positron Corporation